公开(公告)号：KR100697056B1

公开(公告)日：2007-03-20

申请号：KR1020060002253

申请日：2006-01-09

Applicant: 재단법인서울대학교산학협력재단

Inventor： 김상건 ,  김상찬 ,  김영우

IPC: A61K36/484 ,  A61K31/352 ,  A61P1/16

CPC classification number: A61K36/484 ,  A23L33/10 ,  A23L33/105 ,  A23V2002/00 ,  A61K31/352 ,  A23V2250/28 ,  A23V2250/0644 ,  A23V2250/21 ,  A23V2250/032

Abstract: A composition comprising liquiritigenin is provided to be able to inhibit the increase of alanine aminotransferase(ALT) and lactate dehydrogenase(LDH), and significantly decreases necrosis of interstitial cell, thereby being usefully used as a liver disease prophylatic and therapeutic composition. The pharmaceutical composition for preventing and treating liver diseases such as drug induced liver diseases, alcoholic liver diseases, acute hepatitis or chronic hepatitis comprises liquiritigenin as an effective ingredient. The composition further comprises dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate(DDB). Regarding the total composition, 0.1-50 wt.% of the liquiritigenin is contained.

Abstract translation: 提供包含甘草素的组合物能够抑制丙氨酸氨基转移酶（ALT）和乳酸脱氢酶（LDH）的增加，并显着减少间质细胞的坏死，从而有效地用作肝病预防和治疗组合物。 用于预防和治疗肝脏疾病如药物诱发的肝病，酒精性肝病，急性肝炎或慢性肝炎的药物组合物包含甘草素作为有效成分。 组合物还包含二甲基-4,4'-二甲氧基-5,6,5'，6'-二亚甲基二氧联苯-2,2'-二羧酸酯（DDB）。 关于总组合物，含有0.1〜50重量％的甘草素。